Dr. Robert F. Roscigno Ph.D. serves as Senior Vice President - Product Development of the Company. He served as our Senior Vice President, Research and Development from March 2016 until December 2017 and our Vice President, Research and Development from September 2015 until March 2016. From January 2009 to September 2015, Dr. Roscigno served as the executive vice president, global clinical affairs of GeNO, LLC, a pharmaceutical company in the field of inhaled nitric oxide drug products. From July 2007 to January 2009, Dr. Roscigno provided scientific consulting for various companies in the pharmaceutical industry and also worked as a subject matter expert in PAH. From March 2005 to July 2007, Dr. Roscigno was the president and chief operations officer of Lung Rx, Inc., a subsidiary of United Therapeutics Corporation, a biotechnology company. Prior to Lung Rx, Inc., Dr. Roscigno served in multiple leadership positions at United Therapeutics Corporation. Dr. Roscigno graduated from Trinity College with a Bachelor of Science in Biology. He also holds a Doctor of Philosophy in Cell and Molecular Biology from Duke University.
Robert Roscigno is 54, he's been the Senior Vice President - Product Development of Liquidia Corp since 2017. There are 13 older and 7 younger executives at Liquidia Corp. The oldest executive at Liquidia Corp is Ralph Snyderman, 80, who is the Independent Director.
Robert's mailing address filed with the SEC is 419 DAVIS DRIVE, SUITE 100, , MORRISVILLE, NC, 27560.
Over the last 6 years, insiders at Liquidia Corp have traded over 16,750,945$ worth of Liquidia Corp stock and bought 12,456,625 units worth 100,694,400$ . The most active insiders traders include Forest Baskett、Scott D Sandell、Peter J Barris. On average, Liquidia Corp executives and independent directors trade stock every 18 days with the average trade being worth of 1,467,274$. The most recent stock trade was executed by Russell Schundler on 30 August 2024, trading 2,344 units of LQDA stock currently worth 23,792$.
liquidia technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. our proprietary print technology is a simple, elegant solution that solves common problems with drug delivery and efficacy. print technology is a scalable cgmp compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration. liquidia is bringing more efficient, controlled development capabilities to the industry while enhancing the safety and quality of products for patients. liquidia is advancing product candidates from its own pipeline. these initial product candidates, liq861 and liq865, apply the print technology to better drug delivery in inhaled and pain therapeutic areas, respectively. the print technology is also licensed with world-leading pharmaceutical companies that are developing future product candidates.
Liquidia Corp executives and other stock owners filed with the SEC include: